That’s a wrap! VativoRx on TV

That’s a wrap! VativoRx on TV

We have some great news about VativoRx.

For the past year, we’ve been working with an independent video producer to create and air a short-form video segment about how PBMs can do better. Today we can reveal two more details about that partnership:

  • The video will begin airing on PBS stations in the United States in April
  • The video was produced as a segment of Viewpoint Project with Dennis Quaid.

And, starting today, as a visitor to the website, you can see the segment in full right here:

Viewpoint Project with Dennis Quaid specializes in short-form Public Television stories.  Each story highlights specific industries and topics around the world. The show highlights industry professionals and groundbreaking organizations as featured content providers.

Viewpoint Project with Dennis Quaid is created solely for viewing on Public Television stations across the US. Public Television stations receive content from organizations like NETA (National Educational Telecommunications Alliance), from locally produced material and from smaller organizations, such as “Viewpoint Project.” Viewpoint Project with Dennis Quaid operates independently and provides content to Public Television partners by way of satellite uplink.

Viewpoint episodes run as short-form segments between longer programming, generally ranging from three-to-six minutes.

We’re proud to participate in this educational project. 

VativoRx Joins MHA: A New Chapter Begins

The world of healthcare is dynamic, continuously evolving with new challenges and opportunities. At VativoRx, we’ve always believed in the power of innovation, collaboration, and dedication to ensure that we provide the best rebate management solutions in the industry. Today, we’re thrilled to announce our latest milestone: VativoRx is now an official associate member of the Michigan Health & Hospital Association (MHA)!

Read More »

Unveiling the Future: Navigating the Evolving Landscape of 340B Rebates.

The 340B Drug Pricing Program, established in 1992, has been a crucial component of the healthcare system, dedicated to assisting eligible healthcare organizations in serving vulnerable patient populations by granting them access to discounted drugs. At the heart of this program are the 340B rebates, which enable qualifying entities such as safety-net hospitals, community health centers, and other eligible providers to acquire medications at significantly reduced prices.

Read More »
Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »

Biosimilars — Similar But Not Identical

You may have never heard of biosimilar drugs and that’s probably because they are not commonly prescribed in the United States even though they have been around for over 20 years. So, what are biosimilar drugs? A biosimilar drug is no different in terms of safety and effectiveness than a biologic product, also known as a reference product, and while highly similar it is not identical.

Read More »

Lower Cost Prescription Drugs from Canada, Is It Legal?

In the early 2000s, the FDA set up guidelines in the Regulatory Procedures Manual (RPM) that permitted prescription drugs to be imported from other countries if the patient met very strict guidelines. Just stating that the patient needed the drug due to cost savings was not a justification to obtain the drug.

Read More »